Products

Earnings
API

Get in Touch

Contact Us
X (Twitter)
LinkedIn

Resources

Disclaimer: CapyFin provides financial data and AI analysis for informational purposes only and does not provide investment advice or recommendations. Real-time data and AI outputs may be inaccurate, incomplete, delayed, or contain errors or hallucinations. Investing involves risk, including loss of principal. The service is provided “as is” and we disclaim liability to the fullest extent permitted by law. See our Terms of Service and Privacy Policy.

iBio Fiscal Q1 2025 Earnings Report - CapyFin

iBio

🇺🇸 NYSE:IBIO

View Company

Overview Earnings Dividends Seasonality Metrics

Nov 12, 2024

•

Sep 30, 2024

iBio Q1 2025 Earnings Report

iBio reported financial results for the fiscal first quarter ended September 30, 2024.

Key Takeaways

iBio reported no revenue for the first quarter ended September 30, 2024. The net loss from continuing operations was approximately $4.0 million, or $0.46 per share. Cash, cash equivalents and restricted cash totaled approximately $11.3 million.

Advanced myostatin program with dosing underway in non-human primate study.

Collaboration with AstralBio progressed, manufacturing and dosing a lead molecule.

Kristi Sarno was appointed as Senior Vice President of Business Development.

R&D and G&A expenses decreased by approximately 20% due to cash preservation strategy.